{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:19:24Z","timestamp":1792603164330,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK132408"],"award-info":[{"award-number":["DK132408"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40262-025-01564-7","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:33:38Z","timestamp":1756571618000},"page":"1669-1679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Hybrid Population Pharmacokinetic\u2013Machine Learning Modeling to Predict Infliximab Pharmacokinetics in Pediatric and Young Adult Patients with Crohn\u2019s Disease"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0820-1208","authenticated-orcid":false,"given":"Kei","family":"Irie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Minar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Reifenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan M.","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua D.","family":"Noe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey S.","family":"Hyams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"issue":"3","key":"1564_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/j.gastro.2006.12.003","volume":"132","author":"J Hyams","year":"2007","unstructured":"Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn\u2019s disease in children. Gastroenterology. 2007;132(3):863\u201373 (quiz 1165-6).","journal-title":"Gastroenterology"},{"key":"1564_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/ecco-jcc\/jjaa161","volume":"15","author":"PF van Rheenen","year":"2020","unstructured":"van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric Crohn\u2019s disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2020;15:171\u201394.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"1564_CR3","doi-asserted-by":"publisher","first-page":"845","DOI":"10.3390\/jcm14030845","volume":"14","author":"KY Wang","year":"2025","unstructured":"Wang KY, Heikal OS, van Rheenen PF, Touw DJ, Bourgonje AR, Mian P. Clinical and biochemical factors associated with infliximab pharmacokinetics in paediatric patients with inflammatory bowel disease. J Clin Med. 2025;14(3):845.","journal-title":"J Clin Med"},{"issue":"1","key":"1564_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3109\/00365521.2012.741619","volume":"48","author":"A Hamalainen","year":"2013","unstructured":"Hamalainen A, Sipponen T, Kolho KL. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol. 2013;48(1):35\u201341.","journal-title":"Scand J Gastroenterol"},{"issue":"3","key":"1564_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/FTD.0000000000001204","volume":"46","author":"D Alsoud","year":"2024","unstructured":"Alsoud D, Moes D, Wang Z, Soenen R, Layegh Z, Barclay M, et al. Best practice for therapeutic drug monitoring of infliximab: position statement from the international association of therapeutic drug monitoring and clinical toxicology. Ther Drug Monit. 2024;46(3):291\u2013308.","journal-title":"Ther Drug Monit"},{"issue":"24","key":"1564_CR6","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.2174\/0929867324666170911163021","volume":"25","author":"S Lega","year":"2018","unstructured":"Lega S, Bramuzzo M, Dubinsky MC. Therapeutic drug monitoring in pediatric IBD: current application and future perspectives. Curr Med Chem. 2018;25(24):2840\u201354.","journal-title":"Curr Med Chem"},{"issue":"11","key":"1564_CR7","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s11894-023-00895-4","volume":"25","author":"A Samuels","year":"2023","unstructured":"Samuels A, Whaley KG, Minar P. Precision dosing of anti-TNF therapy in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2023;25(11):323\u201332.","journal-title":"Curr Gastroenterol Rep"},{"issue":"11","key":"1564_CR8","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1093\/ibd\/izad277","volume":"30","author":"H Hoelz","year":"2024","unstructured":"Hoelz H, Bragagna L, Litwin A, Koletzko S, Le Thi TG, Schwerd T. Pediatric IBD patients treated with Infliximab and proactive drug monitoring benefit from early concomitant immunomodulatory therapy: a retrospective analysis of a 10-year real-life cohort. Inflamm Bowel Dis. 2024;30(11):2004\u201318.","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"1564_CR9","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/cpt.2148","volume":"109","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, et al. Real-world infliximab pharmacokinetic study informs an electronic health record-embedded dashboard to guide precision dosing in children with Crohn\u2019s disease. Clin Pharmacol Ther. 2021;109(6):1639\u201347.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1564_CR10","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1093\/ibd\/izac237","volume":"29","author":"RJ Colman","year":"2023","unstructured":"Colman RJ, Samuels A, Mizuno T, Punt N, Vinks AA, Minar P. Model-informed precision dosing for biologics is now available at the bedside for patients with inflammatory bowel disease. Inflamm Bowel Dis. 2023;29(8):1342\u20136.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1564_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70086","volume":"18","author":"A Samuels","year":"2025","unstructured":"Samuels A, Irie K, Mizuno T, Reifenberg J, Punt N, Vinks AA, et al. Integrating early response biomarkers in pharmacokinetic models: a novel method to individualize the initial infliximab dose in patients with Crohn\u2019s disease. Clin Transl Sci. 2025;18(2): e70086.","journal-title":"Clin Transl Sci"},{"issue":"9","key":"1564_CR12","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3390\/pharmaceutics13091368","volume":"13","author":"C Schrapel","year":"2021","unstructured":"Schrapel C, Kovar L, Selzer D, Hofmann U, Tran F, Reinisch W, et al. External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics. 2021;13(9):1368.","journal-title":"Pharmaceutics"},{"issue":"9","key":"1564_CR13","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/ibd\/izab285","volume":"28","author":"MC Dubinsky","year":"2022","unstructured":"Dubinsky MC, Mendiolaza ML, Phan BL, Moran HR, Tse SS, Mould DR. Dashboard-driven accelerated infliximab induction dosing increases infliximab durability and reduces immunogenicity. Inflamm Bowel Dis. 2022;28(9):1375\u201385.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"1564_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/FTD.0000000000001078","volume":"45","author":"EA Poweleit","year":"2023","unstructured":"Poweleit EA, Vinks AA, Mizuno T. Artificial intelligence and machine learning approaches to facilitate therapeutic drug management and model-informed precision dosing. Ther Drug Monit. 2023;45(2):143\u201350.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"1564_CR15","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s40262-023-01310-x","volume":"62","author":"K Stankeviciute","year":"2023","unstructured":"Stankeviciute K, Woillard JB, Peck RW, Marquet P, van der Schaar M. Bridging the worlds of pharmacometrics and machine learning. Clin Pharmacokinet. 2023;62(11):1551\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1564_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/cpt.3049","volume":"115","author":"QY Li","year":"2024","unstructured":"Li QY, Tang BH, Wu YE, Yao BF, Zhang W, Zheng Y, et al. Machine learning: a new approach for dose individualization. Clin Pharmacol Ther. 2024;115(4):727\u201344.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"1564_CR17","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/psp4.12684","volume":"10","author":"JH Hughes","year":"2021","unstructured":"Hughes JH, Keizer RJ. A hybrid machine learning\/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors. CPT Pharmacomet Syst Pharmacol. 2021;10(10):1150\u201360.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"11","key":"1564_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/psp4.13019","volume":"12","author":"JH Hughes","year":"2023","unstructured":"Hughes JH, Tong DMH, Burns V, Daly B, Razavi P, Boelens JJ, et al. Clinical decision support for chemotherapy-induced neutropenia using a hybrid pharmacodynamic\/machine learning model. CPT Pharmacomet Syst Pharmacol. 2023;12(11):1764\u201376.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1564_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00499-25","volume":"31","author":"K Chen","year":"2025","unstructured":"Chen K, Wang C, Wei Y, Ma S, Huang W, Dong Y, et al. Machine learning and population pharmacokinetics: a hybrid approach for optimizing vancomycin therapy in sepsis patients. Microbiol Spectr. 2025;31: e0049925.","journal-title":"Microbiol Spectr."},{"issue":"8","key":"1564_CR20","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40262-022-01138-x","volume":"61","author":"A Destere","year":"2022","unstructured":"Destere A, Marquet P, Gandonniere CS, Asberg A, Loustaud-Ratti V, Carrier P, et al. A hybrid model associating population pharmacokinetics with machine learning: a case study with Iohexol clearance estimation. Clin Pharmacokinet. 2022;61(8):1157\u201365.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1564_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s11095-023-03507-y","volume":"40","author":"A Destere","year":"2023","unstructured":"Destere A, Marquet P, Labriffe M, Drici MD, Woillard JB. A hybrid algorithm combining population pharmacokinetic and machine learning for isavuconazole exposure prediction. Pharm Res. 2023;40(4):951\u20139.","journal-title":"Pharm Res"},{"issue":"10","key":"1564_CR22","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/psp4.12689","volume":"10","author":"F Le Louedec","year":"2021","unstructured":"Le Louedec F, Puisset F, Thomas F, Chatelut E, White-Koning M. Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open-source R package mapbayr. CPT Pharmacomet Syst Pharmacol. 2021;10(10):1208\u201320.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1564_CR23","doi-asserted-by":"crossref","unstructured":"Chen T, Guestrin C. XGBoost: A Scalable Tree Boosting System. Proceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining. San Francisco: Association for Computing Machinery; 2016. p. 785\u201394.","DOI":"10.1145\/2939672.2939785"},{"key":"1564_CR24","unstructured":"Kyle TB. mrgsolve: Simulate from ODE-Based Models. 2024."},{"key":"1564_CR25","unstructured":"Felicien. mapbayr: MAP-Bayesian Estimation of PK Parameters. 2023."},{"key":"1564_CR26","unstructured":"David M, Evgenia D, Kurt H, Andreas W, Friedrich L. e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien. 2024."},{"key":"1564_CR27","doi-asserted-by":"crossref","unstructured":"Venables WN, Ripley BD. Modern Applied Statistics with S. Fourth ed. New York; 2002.","DOI":"10.1007\/978-0-387-21706-2"},{"key":"1564_CR28","unstructured":"Andy L, Matthew W. Classification and Regression by randomForest; 2002."},{"issue":"5","key":"1564_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/imj.13412","volume":"47","author":"J Donagher","year":"2017","unstructured":"Donagher J, Martin JH, Barras MA. Individualised medicine: why we need Bayesian dosing. Intern Med J. 2017;47(5):593\u2013600.","journal-title":"Intern Med J"},{"issue":"9","key":"1564_CR30","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1111\/bcp.16126","volume":"90","author":"OS Heikal","year":"2024","unstructured":"Heikal OS, van Rheenen PF, Touw DJ, Kosterink JGW, Maurer M, Koomen JV, et al. Infliximab in paediatric inflammatory bowel disease: external evaluation of population pharmacokinetic models. Br J Clin Pharmacol. 2024;90(9):2200\u201314.","journal-title":"Br J Clin Pharmacol"},{"key":"1564_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2024.154784","volume":"82","author":"MS Tootooni","year":"2024","unstructured":"Tootooni MS, Barreto EF, Wutthisirisart P, Kashani KB, Pasupathy KS. Determining steady-state trough range in vancomycin drug dosing using machine learning. J Crit Care. 2024;82: 154784.","journal-title":"J Crit Care"},{"issue":"1","key":"1564_CR32","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12911-023-02248-7","volume":"23","author":"C Jian","year":"2023","unstructured":"Jian C, Chen S, Wang Z, Zhou Y, Zhang Y, Li Z, et al. Predicting delayed methotrexate elimination in pediatric acute lymphoblastic leukemia patients: an innovative web-based machine learning tool developed through a multicenter, retrospective analysis. BMC Med Inform Decis Mak. 2023;23(1):148.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"2","key":"1564_CR33","doi-asserted-by":"publisher","first-page":"132","DOI":"10.15441\/ceem.23.041","volume":"10","author":"CY Kang","year":"2023","unstructured":"Kang CY, Yoon JH. Current challenges in adopting machine learning to critical care and emergency medicine. Clin Exp Emerg Med. 2023;10(2):132\u20137.","journal-title":"Clin Exp Emerg Med."},{"issue":"3","key":"1564_CR34","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/jcm14030807","volume":"14","author":"HA Ganatra","year":"2025","unstructured":"Ganatra HA. Machine learning in pediatric healthcare: current trends, challenges, and future directions. J Clin Med. 2025;14(3):807.","journal-title":"J Clin Med"},{"issue":"2","key":"1564_CR35","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/psp4.12745","volume":"11","author":"C Maier","year":"2022","unstructured":"Maier C, de Wiljes J, Hartung N, Kloft C, Huisinga W. A continued learning approach for model-informed precision dosing: updating models in clinical practice. CPT Pharmacomet Syst Pharmacol. 2022;11(2):185\u201398.","journal-title":"CPT Pharmacomet Syst Pharmacol"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01564-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T01:03:33Z","timestamp":1763168613000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01564-7","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"1 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. S. H. is on advisory boards for Janssen, Abbvie, Lilly, and Genentech and is a consultant for Takeda and Pfizer. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The datasets analyzed in this study are accessible upon reasonable request by contacting the corresponding author.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The model codes are accessible upon reasonable request by contacting the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The REFINE study received approval from multiple Institutional Review Boards (IRBs), including Cincinnati Children's Hospital Medical Center (CCHMC), Nationwide Children\u2019s Hospital, Medical College of Wisconsin, and Connecticut Children\u2019s Medical Center. Additionally, the CCHMC IRB approved the APPDASH study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from each participant, or from a parent or legal guardian, as appropriate. A waiver of consent was granted when applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.I., P.M., and T.M. wrote the manuscript; K.I., P.M., and T.M. designed the research; K.I., P.M., J.R., B.M.B., J.D.N., J.S.H., and T.M. performed the research; and K.I. and T.M. analyzed the data.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}